Urgent.News

What's breaking now, across hundreds of outlets.

Finance & Markets

Oppenheimer reiterates Capricor stock rating on FDA data robustness

Oppenheimer reiterates Capricor stock rating on FDA data robustness

Oppenheimer has maintained an Outperform rating and set a $54.00 price target for Capricor Therapeutics (NASDAQ:CAPR), following a company webinar that discussed data submitted to the FDA. This rating suggests substantial upside potential from the current stock price of $8.10, which has decreased by 74% over the past six months.

The firm pointed out the strength of their analysis of data from the BLA amendment, which included information from the HOPE-3 trial. The analysis mentioned that over 600 different methods supported roughly a 1-point improvement in treatment effect over placebo for deramiocel efficacy on upper limb function. When both HOPE-2 and HOPE-3 trial results were analyzed together, a 1.29-point PUL 2.0 benefit was found at Month 12, with a p-value of 0.0087.

The 12-month Left Ventricular Ejection Fraction (LVEF) data indicated that deramiocel was 2.21 points ahead in the integrated population and 3.13 points ahead in patients with cardiomyopathy. Matched natural history analyses also demonstrated ongoing preservation of cardiac function. Oppenheimer expressed confidence that the company's package has a higher chance of approval than the current stock price suggests.

According to InvestingPro analysis, the stock appears to be undervalued at its current levels, with a Fair Value of $10.54. The platform provides additional insights through ProTips and comprehensive financial health metrics for investors considering this biotech opportunity. Recent news includes upgrades and regulatory updates for Capricor Therapeutics.

B.Riley upgraded the company's stock to Buy from Neutral, raising its target price to $21, as they anticipate new data at the upcoming PDUFA date on November 22, 2026. Similarly, Piper Sandler upgraded Capricor to Overweight from Neutral, raising its target price to $25, following the FDA's extension of the PDUFA date for the company's deramiocel treatment.

The extension was due to the FDA accepting a major amendment to the Biologics License Application, which included 24-month data from the HOPE-3 trial. These developments highlight Capricor's progress in clinical trials and regulatory reviews, as recognized by multiple analyst firms. Investors are keeping a close eye on the company's upcoming presentations and regulatory milestones.

Rewritten by urgent.news; may contain errors — check the original.

Source: investing.com

Read the original at investing.com →

Report a problem with this story

More in Finance & Markets

More from Thursday 8 October →